- $45.66m
- $50.47m
- $80.28m
Annual income statement for TELA Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 29.5 | 41.4 | 58.5 | 69.3 | 80.3 |
| Cost of Revenue | |||||
| Gross Profit | 18.8 | 27 | 40.1 | 46.5 | 54.3 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 58.9 | 81.7 | 103 | 103 | 115 |
| Operating Profit | -29.5 | -40.2 | -44.1 | -34.1 | -34.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -33.3 | -44.3 | -46.7 | -38 | -38.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -33.3 | -44.3 | -46.7 | -37.8 | -38.8 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -33.3 | -44.3 | -46.7 | -37.8 | -38.8 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -33.3 | -44.3 | -46.7 | -37.8 | -38.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.3 | -2.65 | -2.04 | -1.5 | -0.815 |